Dr. Joyce is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
330 Brookline Ave
Beth Israel Medical Center
Boston, MA 02215Phone+1 617-667-9920Fax+1 617-667-9922
Summary
- Dr. Robin Joyce is an oncologist in Boston, MA and is affiliated with Beth Israel Deaconess Medical Center. She received her medical degree from University of Massachusetts Medical School and has been in practice 25 years. She specializes in hematologic malignancy. She is the director of the clinical lymphoma program. She has expertise in non Hodgkin lymph’s and Hodgkin lymphoma. She also uses cell therapy and transplantation.
Education & Training
Harvard Medical SchoolM.Msc, Clinical Investigation, 1997 - 1998
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1994 - 1997
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Internal Medicine, 1991 - 1994
University of Massachusetts Medical SchoolClass of 1991
Andover Newton Theological SchoolM.Div, Theology, 1981 - 1984- Harvard Medical SchoolMMS, Clinical Investigation
Certifications & Licensure
MA State Medical License 1995 - 2025- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Clinical Trials
- Bortezomib Plus Rituximab for EBV+ PTLD Start of enrollment: 2011 Nov 01
- Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Start of enrollment: 2010 Mar 01
- Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML) Start of enrollment: 2011 Sep 01
Publications & Presentations
PubMed
- High CD34-positive cell dose in matched unrelated donor allogeneic hematopoietic stem cell transplant is not associated with graft-versus-host disease or mortality.Zachary M Avigan, Ajoy L Dias, Laura E Dodge, Jon E Arnason, Robin M Joyce
Transfusion. 2024-06-01 - Comparison of whole-genome and immunoglobulin-based circulating tumor DNA assays in diffuse large B-cell lymphoma.Reid W Merryman, Justin Rhoades, Kan Xiong, Robert A Redd, Katherine Antel
Hemasphere. 2024-04-01 - 7 citationsMinimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.Reid W Merryman, Robert A Redd, Eleanor Taranto, Gulrayz Ahmed, Erin Jeter
Blood Advances. 2023-09-12
Abstracts/Posters
- Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)Robin M. Joyce, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin LymphomaRobin M. Joyce, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...Robin M. Joyce, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
